Advarra signs TransPerfect as strategic language services provider

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/cybrain)
(Image: Getty/cybrain)

Related tags: Clinical trial

Advarra has selected TransPerfect Life Sciences as its strategic supplier of language services, including document translation, digital content localization, and interpretation services.

Advarra – formed recently following the merger of Chesapeake IRB and Schulman IRB​ – provides institutional review board (IRB), institutional biosafety committee (IBC), and global research compliance services.

TransPerfect has been a long-standing partner of both IRBs prior to the merger, Jeff Wendel, Advarra president told Outsourcing-Pharma.com.

"TransPerfect uses the translation memory we’ve built over years of working together to continuously improve translation turnaround times while maintaining high levels of accuracy and quality​," Wendel explained.

"Its TransPort platform provides our staff with transparency into the process, helping us to streamline our internal workflows to meet client timelines,​" he added.

TransPerfect also recently announced that ARCA Biopharma selected its Trial Interactive eTMF solution as its enterprise platform for clinical trials. 

The CO-based biopharmaceutical company used the solution to support a Phase II trial across 50 sites, and moving forward, will transfer all trials to a paperless environment.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars